ATXN3L

Across TCGA pan-cancer cohorts, ATXN3L RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated ATXN3L data layer compared with 4 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher ATXN3L RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATXN3L expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

STAD, ESCA, and UCS are the cancer types where ATXN3L RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Tertile	All	0.473	0.672	.002	72	view →
ESCA	DFS	Tertile	All	0.162	0.518	<.001	45	view →
UCS	DFS	Tertile	IV	0.132	0.718	.002	36	view →
UCEC	DFS	Tertile	IV	0.206	0.704	.033	18	view →
PCPG	DFS	Tertile	All	0.070	0.936	<.001	18	view →
GBM	OS	Tertile	All	0.217	0.420	.022	9	view →
SKCM	DFS	Tertile	III,IV	0.788	0.594	.040	6	view →
KIRP	OS	Tertile	All	0.312	0.727	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ATXN3L–STAD (DFS)

Open the STAD breakdown →